Navigation Links
Transcend Medical Raises $35 Million Series B Round Towards Development of Novel Glaucoma Treatment
Date:6/22/2009

MENLO PARK, Calif., June 22 /PRNewswire/ -- Transcend Medical, Inc., an ophthalmic device company dedicated to delivering breakthrough advances in the treatment of glaucoma, announced today that it has closed a $35 million Series B round and is continuing the rapid development of its Transcend CyPass(TM) System, a novel proprietary system for the minimally-invasive treatment of glaucoma.

Lead investor HLM Venture Partners, along with other new investors Canaan Partners, Technology Partners and Latterell Venture Partners made significant contributions to this round of financing, which was also strongly supported by current investors Morgenthaler Ventures and Split Rock Partners.

"Completing this round is a testament to the progress of our technology and a strong validation of its potential to impact the future of glaucoma treatment," said Brian Walsh, President and Chief Executive Officer of Transcend Medical. "We are now well-capitalized to accomplish all initial clinical and commercial milestones for the company."

The Transcend CyPass System is being developed to both replace current glaucoma therapies, which either lack effectiveness or are very invasive, and to expand treatment to a much larger patient population. Transcend Medical is focused on a less invasive procedure using a novel, proprietary system that reduces intraocular pressure (IOP).

"There is a significant need to improve how we treat glaucoma," commented Eugene de Juan, Jr., M.D., Jean Kelly Stock Distinguished Professor of Ophthalmology at UCSF and Founder of Transcend Medical. "Today's treatment options for glaucoma are highly limited and only feasible in a limited portion of those affected by the disease worldwide."

"We are encouraged by the CyPass System's minimally invasive delivery which is of significant benefit to patients, provides important ease of use features for physicians, and could result in earlier intervention in the glaucoma disease process," added Ike Ahmed, M.D., Assistant Professor, University of Toronto who is a world renowned glaucoma specialist and a clinical investigator of the CyPass System. "The CyPass System has shown promising initial results in a challenging population, with a very straight-forward procedure. We have been quite impressed with our experience to date in this growing patient group."

About Transcend Medical, Inc.

Transcend Medical (www.transcendmedical.com) is focused on the research and development of medical devices for the treatment of glaucoma, the leading cause of adult irreversible blindness. It is estimated that nearly four million people in the U.S. and 70 million worldwide are afflicted with the disease today and the numbers are expected to grow to nearly six million in the U.S. and to over 80 million worldwide by the year 2013. Based in Menlo Park, Calif., Transcend Medical was the first company to be spun out of ForSight Labs (www.forsightlabs.com), an incubator solely focused on ophthalmic innovations.


'/>"/>
SOURCE Transcend Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Life Extension Book, TRANSCEND, Hits Bookstores Today
2. Transcending politics to save lives
3. Transcendental Meditation buffers students against college stress: Study
4. Transcend Medical Announces New President and CEO and Appointment of Chairman of the Board
5. Transcendental meditation effective in reducing high blood pressure, study shows
6. Patients of Courage Transcend Physical Disfigurement, Help Others
7. Physician Dissatisfaction Leads to New Medical Conference
8. Galil Medical Ltd. Sues HealthTronics for Interfering with the Galil/Endocare Merger Agreement
9. CelebrityDiagnosis.com Presents Famous Patients As Medical Lessons
10. Spinal Cancer Patient Finds New Hope at the Palo Alto Medical Foundation
11. U.S. Army Increases Medical and Dental School Benefits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, ... continuation of its strategic partnership with and platinum sponsorship of Global Spine Outreach ... safe and effective management of complex spine deformity cases, particularly in children. , ...
(Date:4/24/2017)... ... 2017 , ... Michael Vick announced his retirement earlier this year from the ... number one pick in the 2001 NFL Draft, to the Atlanta Falcons, made four ... most career rushing yards by a quarterback (6,109) and the most rushing yards by ...
(Date:4/24/2017)... ... 24, 2017 , ... As part of the nationwide Days of Remembrance effort ... the Holocaust and Nazi persecution, Center for Medicine after the Holocaust (CMATH) ... Champions trip to Germany and Poland next week. , The Fourth Biennial CMATH Champions ...
(Date:4/24/2017)... ... 2017 , ... Today, Bright Pink , a national non-profit organization focusing on the prevention ... , Bright Pink is proud to announce Katie Thiede as their new Chief Executive ... role as Chairman of the Board and launched a national search to find a ...
(Date:4/24/2017)... ... ... Veteran Theresa James awoke to the sound of her newly ex-husband breaking ... James depicts every parent’s worst nightmare, when her three children were violently taken from ... throughout my divorce,” James said. “After the death of my children, I continued to ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... Research and Markets has announced the addition ... Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics during ... ... rise from USD 20 Billion in 2015 to around USD 26 ... - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage ...
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
Breaking Medicine Technology: